Increased saturated fatty acids in obesity alter resolution of inflammation in part by stimulating prostaglandin production

Journal of Immunology

Volumn 191, Issue 3, 2013, Pages 1383-1392

  Hellmann, Jason ^a   Zhang, Michael J ^a   Tang, Yunan ^a   Rane, Madhavi ^a   Bhatnagar, Aruni ^a   Spite, Matthew ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; CYCLIC AMP; CYCLOOXYGENASE 2; DP1 PROTEIN; PALMITIC ACID; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E2; PROSTANOID; PROSTANOID RECEPTOR; SATURATED FATTY ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; EXUDATE; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; LIPIDOMICS; MACROPHAGE; MALE; MASS SPECTROMETRY; MOUSE; NEUTROPHIL; NONHUMAN; OBESITY; PERITONEUM; PERITONITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; THYMUS;

ANIMALS; APOPTOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; FATTY ACIDS; HUMANS; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTROPHILS; OBESITY; PALMITIC ACID; PERITONITIS; PHAGOCYTOSIS; PROSTAGLANDIN D2; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; XANTHONES;

EID: 84880651211     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203369     Document Type: Article

References (59)

1. Centers for Disease Control and Prevention (CDC). 2004. Prevalence of overweight and obesity among adults with diagnosed diabetes: United States, 1988-1994 and 1999-2002. MMWR Morb. Mortal. Wkly. Rep. 53: 1066-1068.
2. Roden, M. 2006. Mechanisms of disease: hepatic steatosis in type 2 diabetes: pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2: 335-348.
3. Roger, V. L., A. S. Go, D. M. Lloyd-Jones, E. J. Benjamin, J. D. Berry, W. B. Borden, D. M. Bravata, S. Dai, E. S. Ford, C. S. Fox, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2012. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: e2-e220.
4. Boden, G. 2002. Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care 5: 545-549.
5. Boden, G., and G. I. Shulman. 2002. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and b-cell dysfunction. Eur. J. Clin. Invest. 32(Suppl. 3): 14-23.
6. Fagot-Campagna, A., B. Balkau, D. Simon, J. M. Warnet, J. R. Claude, P. Ducimetiére, and E. Eschwége. 1998. High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int. J. Epidemiol. 27: 808-813.
7. Jouven, X., M. A. Charles, M. Desnos, and P. Ducimetiére. 2001. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 104: 756-761.
8. Hotamisligil, G. S., and E. Erbay. 2008. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 8: 923-934.
9. Shi, H., M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116: 3015-3025.
10. Nguyen, M. T., S. Favelyukis, A. K. Nguyen, D. Reichart, P. A. Scott, A. Jenn, R. Liu-Bryan, C. K. Glass, J. G. Neels, and J. M. Olefsky. 2007. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282: 35279-35292.
11. Kim, F., M. Pham, I. Luttrell, D. D. Bannerman, J. Tupper, J. Thaler, T. R. Hawn, E. W. Raines, and M. W. Schwartz. 2007. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 100: 1589-1596.
12. Wen, H., D. Gris, Y. Lei, S. Jha, L. Zhang, M. T. Huang, W. J. Brickey, and J. P. Ting. 2011. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12: 408-415.
13. Tabas, I., A. Tall, and D. Accili. 2010. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ. Res. 106: 58-67.
14. Ohashi, K., J. L. Parker, N. Ouchi, A. Higuchi, J. A. Vita, N. Gokce, A. A. Pedersen, C. Kalthoff, S. Tullin, A. Sams, et al. 2010. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J. Biol. Chem. 285: 6153-6160.
15. Tang, Y., M. J. Zhang, J. Hellmann, M. Kosuri, A. Bhatnagar, and M. Spite. 2013. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62: 618-627.
16. Jeffcoate, W. J., and K. G. Harding. 2003. Diabetic foot ulcers. Lancet 361: 1545-1551.
17. Johnson, A. R., J. J. Milner, and L. Makowski. 2012. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol. Rev. 249: 218-238.
18. Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8: 349-361.
19. Stables, M. J., and D.W. Gilroy. 2011. Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res. 50: 35-51.
20. Samuelsson, B., R. Morgenstern, and P. J. Jakobsson. 2007. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 59: 207-224.
21. Nathan, C., and A. Ding. 2010. Nonresolving inflammation. Cell 140: 871-882.
22. Serhan, C. N., S. D. Brain, C. D. Buckley, D.W. Gilroy, C. Haslett, L. A. O'Neill, M. Perretti, A. G. Rossi, and J. L. Wallace. 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21: 325-332.
23. Ravichandran, K. S. 2011. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 35: 445-455.
24. Underhill, D. M., and H. S. Goodridge. 2012. Information processing during phagocytosis. Nat. Rev. Immunol. 12: 492-502.
25. Yang, R., N. Chiang, S. F. Oh, and C. N. Serhan. 2011. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr. Protoc. Immunol. Chapter 14: Unit 14.26.
26. Haslett, C., L. A. Guthrie, M. M. Kopaniak, R. B. Johnston, Jr., and P. M. Henson. 1985. Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am. J. Pathol. 119: 101-110.
27. Li, S., Y. Sun, C. P. Liang, E. B. Thorp, S. Han, A. W. Jehle, V. Saraswathi, B. Pridgen, J. E. Kanter, R. Li, et al. 2009. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ. Res. 105: 1072-1082.
28. Rossi, A. G., J. M. Cousin, I. Dransfield, M. F. Lawson, E. R. Chilvers, and C. Haslett. 1995. Agents that elevate cAMP inhibit human neutrophil apoptosis. Biochem. Biophys. Res. Commun. 217: 892-899.
29. Filep, J. G., and D. El Kebir. 2009. Neutrophil apoptosis: a target for enhancing the resolution of inflammation. J. Cell. Biochem. 108: 1039-1046.
30. Klein, J. B., A. Buridi, P. Y. Coxon, M. J. Rane, T. Manning, R. Kettritz, and K. R. McLeish. 2001. Role of extracellular signal-regulated kinase and phosphatidylinositol-3 kinase in chemoattractant and LPS delay of constitutive neutrophil apoptosis. Cell. Signal. 13: 335-343.
31. Gilroy, D. W., P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5: 698-701.
32. Hata, A. N., and R. M. Breyer. 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103: 147-166.
33. Rossi, A. G., J. C. McCutcheon, N. Roy, E. R. Chilvers, C. Haslett, and I. Dransfield. 1998. Regulation of macrophage phagocytosis of apoptotic cells by cAMP. J. Immunol. 160: 3562-3568.
34. Aronoff, D. M., C. Canetti, and M. Peters-Golden. 2004. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol. 173: 559-565.
35. Serezani, C. H., J. Chung, M. N. Ballinger, B. B. Moore, D. M. Aronoff, and M. Peters-Golden. 2007. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am. J. Respir. Cell Mol. Biol. 37: 562-570.
36. O'Brien, B. A., Y. Huang, X. Geng, J. P. Dutz, and D. T. Finegood. 2002. Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 51: 2481-2488.
37. Lee, F. Y., Y. Li, E. K. Yang, S. Q. Yang, H. Z. Lin, M. A. Trush, A. J. Dannenberg, and A. M. Diehl. 1999. Phenotypic abnormalities in macrophages from leptin-deficient, obese mice. Am. J. Physiol. 276: C386-C394.
38. Lecube, A., G. Pachón, J. Petriz, C. Hernández, and R. Simó . 2011. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PLoS ONE 6: e23366.
39. Khanna, S., S. Biswas, Y. Shang, E. Collard, A. Azad, C. Kauh, V. Bhasker, G. M. Gordillo, C. K. Sen, and S. Roy. 2010. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS ONE 5: e9539.
40. Hellmann, J., Y. Tang, and M. Spite. 2012. Proresolving lipid mediators and diabetic wound healing. Curr. Opin. Endocrinol. Diabetes Obes. 19: 104-108.
41. Abrass, C. K., and M. Hori. 1984. Alterations in Fc receptor function of macrophages from streptozotocin-induced diabetic rats. J. Immunol. 133: 1307-1312.
42. Lee, J. Y., K. H. Sohn, S. H. Rhee, and D. Hwang. 2001. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276: 16683-16689.
43. Abramovitz, M., M. Adam, Y. Boie, M. Carriére, D. Denis, C. Godbout, S. Lamontagne, C. Rochette, N. Sawyer, N. M. Tremblay, et al. 2000. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483: 285-293.
44. Dong, L., A. J. Vecchio, N. P. Sharma, B. J. Jurban, M. G. Malkowski, and W. L. Smith. 2011. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J. Biol. Chem. 286: 19035-19046.
45. Yuan, C., R. S. Sidhu, D. V. Kuklev, Y. Kado, M.Wada, I. Song, andW. L. Smith. 2009. Cyclooxygenase allosterism, fatty acid-mediated cross-talk between monomers of cyclooxygenase homodimers. J. Biol. Chem. 284: 10046-10055.
46. Serezani, C. H., S. Kane, A. I. Medeiros, A. M. Cornett, S. H. Kim, M. M. Marques, S. P. Lee, C. Lewis, E. Bourdonnay, M. N. Ballinger, et al. 2012. PTEN directly activates the actin depolymerization factor cofilin-1 during PGE2-mediated inhibition of phagocytosis of fungi. Sci. Signal. 5: ra12.
47. Aronoff, D. M., C. Canetti, C. H. Serezani, M. Luo, and M. Peters-Golden. 2005. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J. Immunol. 174: 595-599.
48. Bryn, T., M. Mahic, J. M. Enserink, F. Schwede, E. M. Aandahl, and K. Taskén. 2006. The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J. Immunol. 176: 7361-7370.
49. Wetzler, C., H. Kämpfer, B. Stallmeyer, J. Pfeilschifter, and S. Frank. 2000. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol. 115: 245-253.
50. Pouliot, M., C. Gilbert, P. Borgeat, P. E. Poubelle, S. Bourgoin, C. Créminon, J. Maclouf, S. R. McColl, and P. H. Naccache. 1998. Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-Activated human neutrophils. FASEB J. 12: 1109-1123.
51. St-Onge, M., N. Flamand, J. Biarc, S. Picard, L. Bouchard, A. A. Dussault, C. Laflamme, M. J. James, G. E. Caughey, L. G. Cleland, et al. 2007. Characterization of prostaglandin E2 generation through the cyclooxygenase (COX)-2 pathway in human neutrophils. Biochim. Biophys. Acta 1771: 1235-1245.
52. Pietramaggiori, G., S. S. Scherer, M. Alperovich, B. Chen, D. P. Orgill, and A. J. Wagers. 2009. Improved cutaneous healing in diabetic mice exposed to healthy peripheral circulation. J. Invest. Dermatol. 129: 2265-2274.
53. Levy, B. D., C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2: 612-619.
54. Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
55. Maderna, P., D. C. Cottell, G. Berlasconi, N. A. Petasis, H. R. Brady, and C. Godson. 2002. Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases. Am. J. Pathol. 160: 2275-2283.
56. Chiang, N., G. Fredman, F. Bäckhed, S. F. Oh, T. Vickery, B. A. Schmidt, and C. N. Serhan. 2012. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484: 524-528.
57. Ikejima, S., S. Sasaki, H. Sashinami, F. Mori, Y. Ogawa, T. Nakamura, Y. Abe, K. Wakabayashi, T. Suda, and A. Nakane. 2005. Impairment of host resistance to Listeria monocytogenes infection in liver of db/db and ob/ob mice. Diabetes 54: 182-189.
58. Mancuso, P. 2013. Obesity and respiratory infections: does excess adiposity weigh down host defense? Pulm. Pharmacol. Ther. 26: 412-419.
59. Corrales-Medina, V. F., J. Valayam, J.A. Serpa, A. M. Rueda, and D. M. Musher. 2011. The obesity paradox in community-Acquired bacterial pneumonia. Int. J. Infect. Dis. 15: e54-e57.